BZ1 Antibody

What is the BZ1 Antibody and what epitopes does it recognize?

BZ1 Antibody is a mouse monoclonal IgG1 kappa light chain antibody that specifically detects the EBV ZEBRA protein (also known as BZLF1, EB1, or Zta). This antibody recognizes epitopes on the full-length recombinant EBV ZEBRA protein, which functions as a transcriptional transactivator that regulates the switch between latent and lytic phases of EBV's lifecycle. The antibody has been extensively validated and cited in over 95 publications for its specificity in detecting ZEBRA of EBV origin .

What validated applications can BZ1 Antibody be used for?

BZ1 Antibody has been validated for multiple research applications:

The antibody is available in both non-conjugated form and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates to accommodate different experimental designs .

How should researchers optimize BZ1 Antibody usage for detection of lytic reactivation?

For optimal detection of EBV lytic reactivation using BZ1 Antibody:

• Timing considerations: ZEBRA expression can be detected as early as 2-4 hours after lytic induction, with protein levels increasing over time. Researchers should design time-course experiments to capture both early and late events of lytic reactivation .

• Controls: Include both positive controls (cells treated with known lytic cycle inducers like TPA, sodium butyrate, or doxycycline in inducible systems) and negative controls (EBV-negative cell lines or primary cells) .

• Co-staining strategy: For comprehensive analysis, consider co-staining with antibodies against other lytic cycle proteins such as Rta (BRLF1), BGLF4, EA-D, VCA, and gp350 to distinguish between complete versus abortive lytic reactivation .

• Fixation method: For immunofluorescence, 4% paraformaldehyde fixation for 15-20 minutes at room temperature yields optimal results for nuclear ZEBRA detection .

How can BZ1 Antibody be used to distinguish between complete and abortive lytic reactivation in experimental models?

Distinguishing complete from abortive lytic reactivation requires strategic use of BZ1 Antibody alongside other markers:

Methodological approach:

• Multi-parameter analysis: Use BZ1 Antibody (1:200 dilution) to detect ZEBRA expression, combined with antibodies against early lytic proteins (BGLF4, EA-D) and late lytic proteins (VCA, gp350).

• Interpretation framework:

  • Complete lytic cycle: Positive for ZEBRA, early lytic proteins, AND late lytic proteins

  • Abortive lytic cycle: Positive for ZEBRA and early lytic proteins, but NEGATIVE for late lytic proteins

For example, research on NPC cells (C666-1) showed an abortive pattern where cells expressed immediate early (Zta, Rta) and early (BGLF4) lytic proteins after BZLF1 activation, but no late lytic proteins (VCA and gp350) were detected. In contrast, SNU719 and C17 cells showed complete lytic cycle with all markers present .

• Virion production assessment: To confirm complete lytic cycle, collect supernatant from BZ1-positive cells and assess for infectious virions by attempting to infect EBV-negative cells (e.g., Akata EBV-negative cells), followed by RT-PCR detection of EBV transcripts in these cells .

What are the technical challenges when using BZ1 Antibody in chromatin immunoprecipitation studies?

Researchers using BZ1 Antibody for ChIP experiments should consider these technical aspects:

• Crosslinking optimization: For studying ZEBRA-DNA interactions, optimal formaldehyde crosslinking (1% for 10 minutes at room temperature) is crucial for preserving protein-DNA complexes without over-fixation .

• Sonication parameters: For mononucleosomal ChIP experiments, sonication conditions must be carefully optimized to achieve chromatin fragments of approximately 150-200bp .

• Sequential ChIP (ReChIP) considerations: When performing ReChIP experiments to detect co-occupancy of ZEBRA with histone marks:

  • BZ1 Antibody performs well in the first round of immunoprecipitation

  • Careful elution conditions are needed to avoid antibody carry-over

  • Control for potential carry-over by replacing either antibody with non-specific IgG in parallel experiments

• Binding site interpretation: Research has demonstrated that ZEBRA can bind nucleosomal DNA both in vivo and in vitro, showing pioneer factor-like activity. ChIP-seq analysis should account for both nucleosome-bound and nucleosome-free binding events .

How can BZ1 Antibody be employed to study ZEBRA interactions with cellular proteins during lytic reactivation?

For investigating ZEBRA protein-protein interactions:

• Co-immunoprecipitation protocol:

  • Prepare nuclear extracts from cells expressing ZEBRA

  • Immunoprecipitate using BZ1 Antibody (recommended dilution 1:50)

  • Analyze co-precipitated proteins by immunoblotting or mass spectrometry

• Known interaction partners: Multiple studies have used BZ1 Antibody to identify ZEBRA interactions with:

  • Chromatin remodeler INO80

  • Ubinuclein-1 (Ubn-1), which inhibits ZEBRA DNA-binding activity

  • Cellular transcription factors like c-Jun, potentially affecting AP1-dependent signaling

• Subcellular localization dynamics: Research has shown that subcellular localization of interaction partners like Ubn-1 changes with cell density and correlates with changes in BZLF1 expression. BZ1 Antibody can be used in co-localization immunofluorescence studies to track these dynamics .

What strategies can overcome challenges when using BZ1 Antibody to evaluate synthetic BZLF1-targeted transcriptional activators?

When using BZ1 Antibody to assess the efficacy of synthetic BZLF1-targeted transcriptional activators:

• Baseline expression assessment: Before induction, establish baseline ZEBRA expression using BZ1 Antibody (1:1000 for Western blot) in your specific cell model, as some EBV-positive cell lines show low constitutive expression .

• Quantification approach: For accurate quantification of ZEBRA induction:

  • Use dual staining with BZ1 Antibody and DNA counterstain

  • Calculate percentage of ZEBRA-positive cells

  • Compare protein levels by densitometry of Western blots using BZ1 Antibody

• Time-course optimization: When evaluating TALE-based or CRISPR-Casilio activator systems targeting BZLF1:

  • Monitor ZEBRA expression at multiple timepoints (2, 4, 7, 15, and 24 hours)

  • Correlate ZEBRA expression with downstream lytic protein expression to assess activator efficiency

• Evaluating cytolytic effects: BZ1 Antibody can be used to correlate ZEBRA expression with cytolytic effects in both in vitro and in vivo models following artificial BZLF1 activation .

What could cause false negative results when using BZ1 Antibody in Western blot analyses?

Several factors can contribute to false negative results when using BZ1 Antibody:

• Protein extraction method: ZEBRA is predominantly nuclear. Use nuclear extraction protocols with high-salt buffers (containing at least 420mM NaCl) to efficiently extract the protein .

• Sample processing: Avoid repeated freeze-thaw cycles of protein samples containing ZEBRA, as the protein may be sensitive to degradation.

• Detection sensitivity: For low ZEBRA expression levels, consider using BZ1-HRP conjugate with enhanced chemiluminescence detection systems, which provides increased sensitivity compared to unconjugated primary antibody .

• Protein modifications: Post-translational modifications of ZEBRA during different phases of lytic cycle may affect epitope recognition. Consider using denaturing conditions and phosphatase inhibitors in extraction buffers .

• Transfer efficiency: ZEBRA protein (~38 kDa) requires standard transfer conditions (100V for 1 hour) using PVDF membranes for optimal results .

How can BZ1 Antibody be integrated into multi-parameter flow cytometry panels for studying EBV lytic reactivation?

For comprehensive flow cytometry analysis:

• Fixation and permeabilization protocol:

  • Fix cells with 2-4% paraformaldehyde (10 minutes)

  • Permeabilize with 0.1-0.5% Triton X-100 or commercial permeabilization reagents

• Optimal panel design:

  • BZ1 Antibody conjugated to fluorochromes compatible with your instrument

  • Include markers for:

    • Apoptosis (Annexin V, cleaved caspase-3)

    • Cell cycle (PI, DAPI)

    • Other EBV lytic proteins

• Gating strategy:

  • First gate on viable cells

  • Identify ZEBRA-positive population

  • Analyze co-expression of other markers within this population

• Controls:

  • Fluorescence-minus-one (FMO) controls

  • Isotype controls matched to BZ1 Antibody

  • EBV-negative cell lines

What experimental design can best elucidate the relationship between ZEBRA's DNA-binding activity and its interaction with chromatin remodelers?

A comprehensive experimental design would include:

• Sequential ChIP-seq approach:

  • First ChIP with BZ1 Antibody to identify ZEBRA binding sites

  • Second ChIP with antibodies against chromatin remodeler components (e.g., INO80)

  • Bioinformatic analysis to identify sites of co-occupancy

• In vitro DNA binding assays:

  • Electrophoretic mobility shift assays (EMSAs) using purified ZEBRA and nucleosomal DNA

  • Compare binding patterns with and without addition of purified chromatin remodelers

  • Use BZ1 Antibody for supershift assays to confirm specificity

• Functional validation:

  • Generate cell lines with knockdown/knockout of specific chromatin remodelers

  • Induce lytic reactivation

  • Use BZ1 Antibody to assess ZEBRA binding to selected promoters by ChIP-qPCR

  • Correlate with expression of downstream lytic genes

Research has demonstrated that ZEBRA can bind nucleosomal DNA both in vivo and in vitro, and its ability to do so may depend on interactions with chromatin remodelers like INO80 .

How can BZ1 Antibody contribute to studies of therapeutic approaches targeting the EBV lytic cycle?

BZ1 Antibody is instrumental in developing and evaluating lytic induction therapy approaches:

• Evaluating TALE-based transcriptional activators:

  • Use BZ1 Antibody to measure ZEBRA induction following treatment

  • Correlate ZEBRA expression levels with downstream lytic protein expression

  • Assess cytotoxic effects in relation to ZEBRA expression levels

• Investigating combination therapies:

  • Monitor ZEBRA expression after treatment with various lytic inducers

  • Compare efficiency of different activators in inducing ZEBRA expression

  • Correlate with susceptibility to antiviral drugs like ganciclovir (GCV)

• In vivo validation:

  • Use BZ1 Antibody for immunohistochemistry on tumor sections from treated animals

  • Quantify percentage of tumor cells expressing ZEBRA

  • Correlate with tumor regression measurements

Research has shown that artificial activation of BZLF1 using synthetic transcriptional activators induces efficient lytic reactivation and cytolytic effects in EBV-positive epithelial cancers both in vitro and in vivo .

What are the methodological considerations for using BZ1 Antibody in research on EBV-specific T cell responses?

When studying EBV-specific T cell responses:

• Detection of ZEBRA-expressing target cells:

  • Use BZ1 Antibody to validate and quantify ZEBRA expression in target cells

  • Consider flow cytometry with BZ1-fluorochrome conjugates for accurate quantification

• T cell recognition assays:

  • Ensure consistent ZEBRA expression in target cells using BZ1 Antibody validation

  • Correlate level of ZEBRA expression with CD4+ T cell recognition efficiency

  • Monitor changes in surface molecules like MHC-II and CD74 in ZEBRA-expressing cells

• Immune evasion studies:

  • Use BZ1 Antibody to confirm ZEBRA expression in cells with impaired T cell recognition

  • Investigate correlation between ZEBRA expression and downregulation of surface CD74

  • Research has shown that BZLF1 can interfere with CD4+ T cell recognition through post-transcriptional downregulation of surface CD74, without affecting MHC-II expression

• In vivo relevance:

  • Use BZ1 Antibody in combination with immune cell markers in tissue sections

  • Analyze spatial relationships between ZEBRA-expressing cells and infiltrating T cells

How can researchers optimize BZ1 Antibody for detecting ZEBRA in clinical specimens?

For clinical specimen analysis:

• Sample preparation optimization:

  • Fresh frozen tissue: Standard fixation in 4% PFA

  • FFPE tissue: Antigen retrieval (citrate buffer pH 6.0, 95°C for 20 minutes)

  • Cytological specimens: Methanol/acetone fixation (1:1, -20°C for 10 minutes)

• Detection sensitivity enhancement:

  • Use tyramide signal amplification systems with BZ1-HRP

  • Consider multiplex immunofluorescence with spectral unmixing

  • Implement automated quantitative analysis software

• Validation approach:

  • Use alternative methods (e.g., RT-qPCR for BZLF1 mRNA) to confirm results

  • Include appropriate positive controls (e.g., lytically induced cell lines)

  • Compare results with detection of other viral lytic gene products

• Clinical correlation studies:

  • Correlate BZ1 Antibody staining patterns with clinical outcomes

  • Develop standardized scoring systems based on percentage of positive cells and intensity

Research suggests that detection of ZEBRA in clinical specimens may have diagnostic and prognostic value, particularly in EBV-associated malignancies .